328 related articles for article (PubMed ID: 10681383)
1. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.
Wang RW; Newton DJ; Liu N; Atkins WM; Lu AY
Drug Metab Dispos; 2000 Mar; 28(3):360-6. PubMed ID: 10681383
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.
Yamazaki H; Nakajima M; Nakamura M; Asahi S; Shimada N; Gillam EM; Guengerich FP; Shimada T; Yokoi T
Drug Metab Dispos; 1999 Sep; 27(9):999-1004. PubMed ID: 10460798
[TBL] [Abstract][Full Text] [Related]
3. Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human.
Emoto C; Yamazaki H; Iketaki H; Yamasaki S; Satoh T; Shimizu R; Suzuki S; Shimada N; Nakajima M; Yokoi T
Xenobiotica; 2001 May; 31(5):265-75. PubMed ID: 11491388
[TBL] [Abstract][Full Text] [Related]
4. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
5. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes.
Yamazaki H; Nakano M; Imai Y; Ueng YF; Guengerich FP; Shimada T
Arch Biochem Biophys; 1996 Jan; 325(2):174-82. PubMed ID: 8561495
[TBL] [Abstract][Full Text] [Related]
6. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Patki KC; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Jul; 31(7):938-44. PubMed ID: 12814972
[TBL] [Abstract][Full Text] [Related]
7. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.
Kenworthy KE; Bloomer JC; Clarke SE; Houston JB
Br J Clin Pharmacol; 1999 Nov; 48(5):716-27. PubMed ID: 10594474
[TBL] [Abstract][Full Text] [Related]
8. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.
Galetin A; Clarke SE; Houston JB
Drug Metab Dispos; 2003 Sep; 31(9):1108-16. PubMed ID: 12920166
[TBL] [Abstract][Full Text] [Related]
9. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
Zhang ZY; King BM; Pelletier RD; Wong YN
Cancer Chemother Pharmacol; 2008 Sep; 62(4):707-16. PubMed ID: 18431572
[TBL] [Abstract][Full Text] [Related]
10. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.
Shaw PM; Hosea NA; Thompson DV; Lenius JM; Guengerich FP
Arch Biochem Biophys; 1997 Dec; 348(1):107-15. PubMed ID: 9390180
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
13. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains.
Schrag ML; Wienkers LC
Arch Biochem Biophys; 2001 Jul; 391(1):49-55. PubMed ID: 11414684
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns.
Emoto C; Iwasaki K
Xenobiotica; 2006; 36(2-3):219-33. PubMed ID: 16702113
[TBL] [Abstract][Full Text] [Related]
16. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis.
Wang RW; Newton DJ; Scheri TD; Lu AY
Drug Metab Dispos; 1997 Apr; 25(4):502-7. PubMed ID: 9107550
[TBL] [Abstract][Full Text] [Related]
17. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
18. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.
Miyazaki M; Nakamura K; Fujita Y; Guengerich FP; Horiuchi R; Yamamoto K
Drug Metab Dispos; 2008 Nov; 36(11):2287-91. PubMed ID: 18669585
[TBL] [Abstract][Full Text] [Related]
19. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.
Stresser DM; Blanchard AP; Turner SD; Erve JC; Dandeneau AA; Miller VP; Crespi CL
Drug Metab Dispos; 2000 Dec; 28(12):1440-8. PubMed ID: 11095581
[TBL] [Abstract][Full Text] [Related]
20. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
Shen L; Fitzloff JF; Cook CS
Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
